Cytori Therapeutics Shares Up 29.5% (But Down 18% From Pre-Market High); Co. Earlier Issued Press Release Highlighting Publication In 'Gastroenterology' Of Trial Results For Crohn's Disease Treatment Earlier This Month
Benzinga Newsdesk